Auteur/autrice : contact@xenothera.com

[Newsletter -3] NEWS/INFOS

May 15, 2020. >> Official news bulletin for XAV-19/Bulletin officiel du XAV-19 << Download our newsletter (english version) Télécharger notre newsletter (version française)

[Newsletter -2] NEWS /INFOS

May 8, 2020. >> Official news bulletin for XAV-19/Bulletin officiel du XAV-19 << Download our newsletter (english version) Télécharger notre newsletter (version française)

Covid-19 : Xenothera cherche les moyens de finaliser un traitement

[Article presse ] Par Frédéric Thual- La Tribune , à Nantes  |  26/03/2020, 15:08 Avec son XAV-19, un mix d’anticorps protecteurs similaires à la réponse naturelle de l’homme, la société de biotechnologie nantaise Xenothera, affirme détenir une clé thérapeutique pour traiter les infections à coronavirus, dont celle du Covid-19.  La start-up, qui estime que les lots pourraient être disponibles…
Lire la suite

Interview d’Odile Duvaux, présidente de Xenothera dans Les Echos

[Article Presse] Par Emmanuel Guimard Publié le 20 mars 2020 à 17h14 Xenothera veut réactiver ses anticorps polyclonaux contre le coronavirus. Cette société de biotechnologies nantaise veut lever 3 millions d’euros dans l’urgence, pour réactiver une solution thérapeutique qui permettra de réorienter ses anticorps polyclonaux « humanisés » contre le coronavirus. C’est un projet sur lequel Xenothera a…
Lire la suite

Le XAV-19 de XENOTHERA, un traitement prometteur pour les cas graves de Coronavirus

[Communiqué ] Nantes , le 19 mars 2020 XENOTHERA pense détenir aujourd’hui une clé thérapeutique pour les infections à coronavirus, aussi bien pour la pandémie actuelle que pour les futures infections. Il est insoutenable de penser qu’aujourd’hui de nombreux patients décèdent faute de traitement efficace contre le virus. XENOTHERA détient une technologie unique de production…
Lire la suite

Xenothera presents at Toulouse ONCOWEEK 2020

At ONCOWEEK 2020 that will take place in Toulouse on Feb. 3-5, Xenothera will present original data from its Glyco-Humanized Polyclonal Antibodies (GH-pAb) platform. Scientists from Xenothera found that pAbs raised against given tumor cells show specificity, inhibit tumor growth, synergize with immune checkpoint inhibitors and owing to their mechanism of action induce conversion of…
Lire la suite

The first patient has been injected 2 weeks ago

[ Communiqué ] Nantes, December 12th, 2019 XENOTHERA is pleased to give you some updates on the development of our portfolio. After receiving approval to start the Phase I/II clinical trial for our LIS1 product developed as induction treatment in solid organ transplantation, the first patient has been injected 2 weeks ago. The DSMB has approved…
Lire la suite

Xenothera receives approval for first in man Kidney Transplant Clinical Trial

Nantes, September 11th, 2019 – Xenothera announces it has received  Czech Republic regulatory agency approval to begin its Phase I/II clinical trial of its LIS1 product developed as induction treatment in solid organ transplantation. Xenothera plans to initiate a mono centric trial with volunteering kidney transplant patients. The clinical trial is planned at the Praha Institute for Clinical…
Lire la suite

Xenothera presents at ESOT 2019

XENOTHERA will participate at ESOT 2019 that will take place in Copenhagen in Sept.19.During the congress the preclinical data obtained with the first product, LIS1, for prevention of graft rejection, will be presented by Bernard Vanhove, COO, and Juliette Rousse, PhD student.In the first two communications, the original data obtained with LIS1 in non-human primates…
Lire la suite

Xenothera Announces Publication in European Journal of Clinical Investigation on Immunological Mechanisms Underlining Use of LIS1

Kidney graft recipients receiving anti-lymphocyte globulins of animal origin undergo unwanted immune responses against Neu5GC carbohydrate antigens related to safety concerns, endothelial inflammation and possibly rejection. Xenothera’s LIS1 is a next-generation engineered Anti-Lymphocyte Globulins which does not elicit responses against Neu5GC carbohydrate antigens. Nantes, February 28, 2019 – Xenothera announced publication in European Journal of…
Lire la suite